Anti-ILT4 antibodies and antigen-binding fragments
Inventors
Blanusa, Milan • Joyce-Shaikh, Barbara • Schuster, Andrea Claudia • Schultze, Kornelia • Zuniga, Luis A.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11897957-B2
Publication Date
2024-02-13
Expiration Date
Abstract
The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.
Core Innovation
The invention describes treating a cancer in a human subject by administering an effective amount of an antibody or antigen-binding fragment that binds human ILT4. The antibody comprises a heavy chain variable domain defined by CDR-H1 GYYWS, CDR-H2 EINHSGSTNYNPSLKS or EINHAGSTNYNPSLKS, and CDR-H3 LPTRWVTTRYFDL, together with a light chain variable domain defined by CDR-L1 TGSSSNIGAGYDVH, CDR-L2 selected from GNSNRPS, GQSNRPS, GESNRPS, GDSNRPS, GNANRPS, GQANRPS, GEANRPS, or GDANRPS, and CDR-L3 QSFDNSLSAYV.
The invention further provides a method for blocking binding of ILT4 to HLA-G, HLA-A, HLA-B and/or HLA-F in a human subject. This blocking method includes administering an effective amount of an antibody or antigen-binding fragment that binds human ILT4, where the antibody variable domains include the defined CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 sequences.
Claims Coverage
The claim coverage includes four independent claims, centered on administering ILT4-binding antibodies defined by specific heavy-chain and light-chain CDR amino acid sequences for cancer treatment or for blocking ILT4 binding to HLA-G, HLA-A, HLA-B and/or HLA-F.
Cancer treatment with ILT4-binding antibody variable domains defined by CDR sequences
A method of treating a cancer in a human subject comprising administering an effective amount of an antibody or antigen-binding fragment that binds human ILT4, wherein the antibody comprises a heavy chain variable domain with CDR-H1 GYYWS, CDR-H2 EINHSGSTNYNPSLKS or EINHAGSTNYNPSLKS, and CDR-H3 LPTRWVTTRYFDL, and a light chain variable domain with CDR-L1 TGSSSNIGAGYDVH, CDR-L2 selected from GNSNRPS, GQSNRPS, GESNRPS, GDSNRPS, GNANRPS, GQANRPS, GEANRPS, or GDANRPS, and CDR-L3 QSFDNSLSAYV.
Cancer treatment with ILT4-binding antibody variable domains defined by a specific CDR set
A method of treating a cancer in a human subject comprising administering an effective amount of an antibody or antigen-binding fragment that binds human ILT4, wherein the antibody comprises a heavy chain variable domain with CDR-H1 GYYWS, CDR-H2 EINHAGSTNYNPSLKS, and CDR-H3 LPTRWVTTRYFDL, and a light chain variable domain with CDR-L1 TGSSSNIGAGYDVH, CDR-L2 GDSNRPS, and CDR-L3 QSFDNSLSAYV.
Blocking ILT4 binding to HLA-G, HLA-A, HLA-B and/or HLA-F with ILT4-binding antibody variable domains defined by CDR sequences
A method for blocking binding of ILT4 to HLA-G, HLA-A, HLA-B and/or HLA-F in a human subject comprising administering an effective amount of an antibody or antigen-binding fragment that binds human ILT4, wherein the antibody comprises a heavy chain variable domain with CDR-H1 GYYWS, CDR-H2 EINHSGSTNYNPSLKS or EINHAGSTNYNPSLKS, and CDR-H3 LPTRWVTTRYFDL, and a light chain variable domain with CDR-L1 TGSSSNIGAGYDVH, CDR-L2 selected from GNSNRPS, GQSNRPS, GESNRPS, GDSNRPS, GNANRPS, GQANRPS, GEANRPS, or GDANRPS, and CDR-L3 QSFDNSLSAYV.
The inventive scope is centered on administering ILT4-binding antibodies defined by specific heavy-chain and light-chain CDR amino acid sequences, for either cancer treatment or blocking ILT4 binding to specified HLA ligands.
Stated Advantages
Treating a cancer in a human subject.
Blocking binding of ILT4 to HLA-G, HLA-A, HLA-B and/or HLA-F.
Allows treatment of cancer in a human subject using an ILT4-binding antibody or antigen-binding fragment.
Provides a method to block ILT4 binding to HLA-G, HLA-A, HLA-B and/or HLA-F in a human subject.
Documented Applications
Treating a cancer in a human subject in need thereof by administering an ILT4-binding antibody or antigen-binding fragment comprising specified CDR sequences.
Blocking binding of ILT4 to HLA-G, HLA-A, HLA-B and/or HLA-F in a human subject by administering an ILT4-binding antibody or antigen-binding fragment comprising specified CDR sequences.
Interested in licensing this patent?